In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma Quarterly Deal-Making Statistics, Q2 2017

A look at financing, M&A and alliance activity April–June 2017

Executive Summary

Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.


Related Content

Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs
Biogen's Neuroscience Strategy Includes De-Risking The Pipeline
Heptares' GPCR Discovery Pact With PeptiDream Focused On Inflammation
Chinese Investor Consortium Buys SciClone But Relisting Possible
Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor
Bioverativ Fills Gap In Pipeline With $400m True North Buy
AstraZeneca Taps Pieris For Inhaled Asthma Anticalins
Fresenius Covers All Bases With Akorn Acquisition And Merck Biosimilar Buy
Biogen Staying "Laser-Focused" On Neuroscience
Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts